Lantern Pharma (NASDAQ:LTRN) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) announced its quarterly earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Stock Down 2.4 %

Shares of NASDAQ LTRN traded down $0.09 during midday trading on Friday, hitting $3.63. The stock had a trading volume of 33,673 shares, compared to its average volume of 85,050. The business’s 50 day moving average is $4.26 and its 200-day moving average is $3.78. Lantern Pharma has a 52 week low of $2.79 and a 52 week high of $9.96. The company has a market cap of $39.15 million, a P/E ratio of -2.04 and a beta of 1.64.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.